



TM


02 January 2026

Pharma and Healthcare

Generic semaglutide – over Rs 50bn opportunity

INDUSTRY UPDATE

BSE Healthcare v/s BSE Sensex



Source: Bloomberg, Systematix Institutional Research

Company recommendations

Company	TP (Rs)	Reco
AJP	3,293	BUY
CIPLA	1,781	BUY
DIVI	5,487	SELL
DRRD	1,156	HOLD
JUBLPHAR	1,238	HOLD
KRSNAA	949	BUY
LPC	2,064	HOLD
MANKIND	2,425	HOLD
ORCP	1,041	BUY
PFIZ	6,375	HOLD
PLM	1,781	HOLD
RAINBOW	1,670	BUY
SHEP	3,034	BUY
SLPA	392	HOLD
SUNP	1,781	BUY
ZYDUSLIF	938	HOLD

Source: Systematix Institutional Research;

Vishal Manchanda

vishalmanchanda@systematixgroup.in
+91 97374 37148

Virti Shah

virtishah@systematixgroup.in
+91 22 6704 8099

Rushank Mody, CFA

rushankmody@systematixgroup.in
+91 22 6704 8046

Patent expiry of semaglutide in India, emerging markets and regulated markets (Brazil, Canada) could create an incremental Rs 50bn+ revenue opportunity for generic versions over the next 12-15 months. This opportunity is likely to be shared among 10-15 players, comprising Indian and global generic manufacturers. For FY27E, we see this as a Rs 10-Rs 20bn incremental revenue opportunity in India branded formulation space, ~Rs 45bn in regulated markets (Canada and Brazil) and Rs 5bn-Rs 10bn for emerging markets (EM). The regulated markets opportunity can be large in the near term, but should gradually subside over time. In addition, there are also meaningful risks – regulatory and commercial risks. India and EM opportunity may not become as large imminently, but will keep expanding over years. The regulatory risks are also lower in India and EM. Indian players that stand to benefit the most are Sun Pharma (SUNP), Dr. Reddy's (DRRD), Eris Lifesciences (ERIS), Cipla (CIPLA), One Source Speciality Pharma (ONESOURC), Torrent Pharma (TRP), Lupin (LPC), Alkem (ALKEM), Zydus Lifesciences (ZYDUSLIF), Ajanta (AJP) and Biocon (BIOS). Shaily Engineering Plastics (SHEP) will also benefit meaningfully, as one of the few global suppliers of pen device to these front-end generic companies.

• India launch can add about 0.5%-1% to IPM growth in FY27

We expect the adoption of GLP-1 therapy among diabetics to rise sharply, following the launch of generic semaglutide version in 1QFY27, driven by a affordable price point - potentially 30% to 50% lower versus the current level. Over time, prices could further correct as low as 70%-75% from current levels. Market share within the GLP-1 segment may remain concentrated among the top Top 5-10 players, including Novo Nordisk (NOVOB)/ Emcure (EMCURE), SUNP, Eris, CIPLA, LPC, TRP, DRRD, ALKEM and ZYDUSLIF. At present, only ALKEM, DRRD and SUNP have approvals from the Indian drug regulator for their generic versions, with the same pending for other players. ZYDUSLIF is pursuing a differentiated semaglutide injection with some competitive advantage versus peers, which could offset its relatively weaker presence in diabetes therapy.

• Launch in regulated markets (Canada and Brazil): Higher uncertainty due to competitive and approval risks

The combined semaglutide market in Brazil and Canada is estimated at ~USD 2bn in annual sales. Assuming a 50% price erosion following the generic entry and 50% market share capture by generics, the addressable opportunity for generics players could be ~ USD 500mn. However timely approvals in these markets are critical to its success. We estimate there are 7-8 generics filers in Canada about 12 in Brazil. DRRD potentially could be the first generic player among Indian companies to launch in Canada, while SUNP may have the first-mover advantage in Brazil. Other Indian players in fray for Brazil include, TRP, CIPLA, ZYDUSLIF and BIOS (partnered with BIOMM ZK). Notably, SUNP and DRRD are the only Indian players that have filed in Canada.

• Launch in EMs: SUNP, DRRD and Alkem may be better positioned

DRRD, BIOS, ONESOURC appear better positioned to monetize the opportunity in EMs. AJP, through its tie up with BIOS and a strong existing footprint in diabetes therapies across African markets, is also well placed to succeed. Plus, semaglutide API manufacturers could also benefit from more penetration in EMs.

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Vishal Manchanda, Virti Shah, Rushank Mody, CFA**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

- The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

- There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not show that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed, and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 34600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | Investment Advisor SEBI Reg. No. INA000010414 | AMFI : ARN - 64917